iBio announced signing of agreements with Infectious Disease Research Institute in support of iBio’s SARS-CoV-2 Virus-Like Particle vaccine development
| | | | |

iBio announced signing of agreements with Infectious Disease Research Institute in support of iBio’s SARS-CoV-2 Virus-Like Particle vaccine development

On Apr. 9, 2020, iBio announced the signing of two agreements with the Infectious Disease Research Institute (IDRI)…

AIM ImmunoTech announced NCI award of $14.54 million to study Ampligen as part of five Roswell Park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers

AIM ImmunoTech announced NCI award of $14.54 million to study Ampligen as part of five Roswell Park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers

On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center…